Short Interest in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Expands By 650.4%

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,550,000 shares, an increase of 650.4% from the March 15th total of 339,800 shares. Based on an average daily volume of 6,980,000 shares, the short-interest ratio is presently 0.4 days. Approximately 12.2% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of TransCode Therapeutics in a research report on Thursday, March 13th.

TransCode Therapeutics Trading Up 1.5 %

RNAZ stock traded up $0.01 during mid-day trading on Monday, hitting $0.41. 1,606,873 shares of the stock were exchanged, compared to its average volume of 1,867,996. The business has a fifty day moving average price of $3.57 and a 200 day moving average price of $183.95. TransCode Therapeutics has a 12 month low of $0.34 and a 12 month high of $66.33.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.